Clicks Group, a diversified retailer, has announced plans to sell its stake in Unicorn Pharmaceuticals, its manufacturing subsidiary. This decision follows a Constitutional Court ruling in March 2023 that barred Clicks from owning pharmacies while producing its own generic drugs. As a result, the Department of Health halted processing new pharmacy license applications until Clicks complied with the ruling. After engaging with health officials, Clicks proposed divesting from Unicorn Pharmaceuticals to align with regulatory requirements. The sale, expected to conclude by the end of July, aims to resolve an eight-year legal dispute initiated by the Independent Community Pharmacy Association (ICPA).
.
Read the full article on the Money Web.